Project Grant HT94252310707
Award Date
7/1/23
Completion Date
6/30/26
Dollars Obligated
$799K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This federal Project Grant award, valued at $1,235,845.00 and awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The project, with a performance period from August 15, 2025 to August 14, 2028, will leverage data science methods to transform healthcare for military service members and the broader public. The...
The Defense Health Agency awarded a $1,398,689 Project Grant to the University of Illinois under the Military Medical Research and Development program (CFDA 12.420) to support research on "Pharmacologic Downregulation of SOX2 to Enhance Efficacy of Anti-AR Therapies in Prostate Cancer". The project aims to investigate methods for improving the effectiveness of anti-androgen therapies for prostate cancer through modulating the SOX2 protein. The award will fund this 3-year research...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,602,572.00 in funding to the University of Illinois to support research on the role of the novel hexokinase HKDC1 in hepatocellular carcinoma. The award has a performance period from July 15, 2024 to July 14, 2027. The University of Illinois, a major public research university in Chicago, will conduct innovative scientific studies to advance...
The University of Illinois was awarded a $719,550 Project Grant from the Defense Health Agency under the CFDA Program 12.420 - Military Medical Research and Development. The grant, with an April 1, 2024 award date and March 31, 2027 completion date, will support research on the TRKA-MLK3 axis as an actionable target in triple-negative breast cancer. The project aims to advance scientific understanding and develop new treatments related to this specific type of breast cancer, which is a key...
The University of Illinois received a $690,539 project grant award from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 through July 31, 2026 to investigate G0S2 as a master regulator of the local estrogenic environment during breast cancer progression and antiestrogen therapy. Through this award, the University will conduct scientific research that aims to transform healthcare for service...
The Defense Health Agency awarded a $1,117,352 Project Grant to Trustees of Boston University's Boston University Medical Campus to develop a novel and practical intervention for detoxification of per- and polyfluoroalkyl substances (PFAS) in humans. The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports the university's research to transform health care for Service Members and the public through innovative biomedical research. As part of the...
This Project Grant award, valued at $293,978.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports research on "Cognition, Vascular Function, and Physical Activity in Multiple Sclerosis" to be conducted by the University of Illinois in Chicago, Illinois. The research aims to explore innovative approaches to disease prevention, diagnosis, treatment, and management of conditions relevant...
The University of Illinois was awarded a $1,499,728 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on July 1, 2023, will fund research to investigate a novel approach to reverse volumetric muscle loss following transfemoral amputations, with the goal of improving mobility and function. The research aims to transform health care for service members and the American public through innovative biomedical...
The University of Illinois was awarded a $713,985 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2025 to investigate PAX8 as a drug target for high-grade serous ovarian cancer. Through this funding, the University of Illinois will support applied biomedical research efforts to develop medical solutions for cancer....
This $701,121 federal Project Grant award from the Department of Defense's Defense Health Agency, issued under the Military Medical Research and Development program (CFDA 12.420), supports research on the ovarian-disrupting effects and mechanisms of per- and polyfluoroalkyl substances (PFAS). The project is being conducted by Rutgers, The State University of New Jersey's RBHS-School of Nursing over a 3-year period from September 2023 to September 2026. The research aims to develop a better...